Please login to the form below
Sting agonists
This page shows the latest Sting agonists news and features for those working in and with pharma, biotech and healthcare.
BioNTech and Ryvu partner to develop immuno-modulatory small molecule candidates
combinations. The STING pathway plays a critical role during infections and autoimmune disease, as well as one of the key innate immunity pathways responsible for antitumour immunity. ... Ryvu’s STING agonists have already shown promising results in
Latest news
-
Bayer signs €250m pact with India’s Curadev for STING drugs
More than a dozen biopharma companies have been looking at STING agonists as potential treatments for cancer by switching on the inflammatory response against tumour cells, including Merck &Co and Novartis. ... There’s still interest in STING agonists,
-
AbbVie cures STING fever with Mavupharma acquisition
Terms of the deal haven’t been disclosed. There has been a rush to bring STING agonists forward into clinical trials, in the hope that they could enhance the activity of ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop
-
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
-
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
also that the STING agonists were speculated to be more potent based on biology and some preclinical studies. ... Now, they say “the apparent comparable potency between the two classes of agents, a potentially worse safety profile for STING, and the
-
Novartis steps up its efforts in immuno-oncology
The collaboration with California-based Aduro is focused on the development of cancer immunotherapies based on the STING (Stimulator of Interferon Genes) receptor that - when activated - is through to initiate a ... On the other hand, Aduro's STING
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
There are various companies working on toll-like receptor agonists that stimulate antigen-presenting cells, such as Idera’s TLR9-targeted drug IMO-2125 which boosted the activity of BMS’ CTLA4 ... Among the plethora in the pipeline, Aurigene and BMS
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Springer Nature
Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
